(RTTNews) – The shares of Inovio Pharmaceuticals, Inc. (INO) fell by 30% on Monday morning after the biotechnology company announced that testing 2/3 of its COVID-19 candidate vaccine would be delayed after the US FDA announced that testing 2/3 of its COVID-19 candidate vaccine would be delayed after the US FDA was in charge of testing 2/3 of its COVID-19 candidate vaccine. But it’s not the first time I suspended her.
The INO is lately at $11. 75, down $5. 19 or 30. 64% on the Nasdaq.
INOVIO said the FDA informed the company that it had further questions about the company’s 2/3 trial of its COVID-19 INO-4800 vaccine candidate. clinical suspension.
The company said partial clinical suspension is not due to adverse situations similar to its ongoing extended Phase 1 examination of INO-4800.